Fenix ... As a medical professional on the "corporate/business" side of things, I agree wholeheartedly with your assessement on the challenges to RVX-208 on such a broad range of potential efficacies, from my POV.

Behold: A Miracle Drug! ... well, scientists don't believe in miracles. Further, other drugs in the past have burnt patients and doctors when jumping onto the train too early.

So, the good news ... there is a P3 study underway, nearing completion, to assess ONE indication for RVX-208 :)

All of these "other" indications and opportunities are wonderful, however, they can confuse and detract in a different and odd way from the very simple question of whether RVX-208 significantly helps diabetic cardiopathy patients when combined with statins.

I have been maintaining that I just want to see positive data for that one simple disease state for CREDIBILITY, and a proven "safe and effective" label for RVX-208.

The doors can then fly wide open (then), as attention turns to "other" promising data, more studies, calculable potential values, and even off label utilization potentially ..... 

Fisrt things first though ... positive data for the primary endpoints of BetonMace ... (plus) hopefully very promising secondary data "for further contemplation" medically and financially for some other stuff.

That is how I would think and hope medical acceptance comes to be ... one "digestible" step at a time ... but with a lot of excitement and anticipation for Resverlogix technology to blossom in many more directions through study, upon establishing an initial critical credibility standard. 

Thank you for your insights and opinions by the way, it's very interesting on the frontier.